Compare Medtronic PLC (MDT) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Marathon Petroleum Corp — how do they compare? Medtronic PLC trades at $82.58 (market cap $106.61B), while Marathon Petroleum Corp trades at $317.42 (market cap $92.05B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | MPC | |
|---|---|---|
Market Cap | $106.61B | $92.05B |
Sector | Health | Energy |
52-Week High | $105.35 | $315.31 |
52-Week Low | $73.75 | $158.59 |
Enterprise Value | $125.36B | $124.23B |
Dividend Yield | 3.46% | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Marathon Petroleum (MPC) trades at $317.00, up 1.41% today, reflecting strong momentum amid bullish technical signals and positive analyst sentiment. The stock shows robust fundamentals with a P/E of 20.58, P/S of 0.7, and ROE of 27.92%, supported by recent earnings beats in Q4 2025 and Q1 2026. Cash flow trends indicate operational strength with $8.25B from operations in 2025, while refining margins drive profitability, as highlighted in recent Zacks reports (July 2026).
Outlook remains positive with 76% analyst buy ratings and a consensus price target of $292.70, though risks include volatile energy markets and rising debt-to-asset ratios. The stock's proximity to resistance at $317 suggests potential consolidation, but sustained refining advantages and institutional support offer upside potential for investors focused on energy sector growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
